Section Structure
1. Highlights
2. Clinical Background
3. Study Design and Quality Improvement Intervention
4. Main Results
5. Clinical Interpretation
6. Strengths and Limitations
7. Implications for Emergency and Otolaryngology Practice
8. Funding, Registration, and Citation
9. Conclusion
Highlights
Nebulized tranexamic acid (TXA), embedded within a clinical care guideline (CCG) and emergency department order set, achieved very high implementation fidelity for post-tonsillectomy hemorrhage (PTH), with order set use in 95.7% of eligible treated patients.
After guideline implementation, the proportion of patients with PTH requiring operative management fell from 50.0% to 27.1%, corresponding to an absolute risk reduction of 0.320 with a 95% confidence interval of 0.116 to 0.500.
The study addresses a practical translational problem: how to move a promising but inconsistently used therapy into routine hospital workflow despite turnover in staff, formulary constraints, and variable clinician awareness.
Although the study supports a potentially important non-operative strategy, the findings arise from a pre-post quality improvement design rather than a randomized comparison, so residual confounding and temporal bias remain possible.
Clinical Background
Post-tonsillectomy hemorrhage is among the most consequential complications after tonsillectomy. It creates a high-stakes intersection between emergency medicine, perioperative care, and otolaryngology because patients can deteriorate quickly, often present unexpectedly, and may require urgent airway protection or operative hemostasis. Even when bleeding appears limited on arrival, recurrent bleeding, clot dislodgement, and aspiration risk can rapidly change the clinical picture.
Historically, management of PTH in the emergency department has focused on triage, resuscitation, suctioning, visualization, otolaryngology consultation, and preparation for operating room control when necessary. Yet not every patient with PTH requires surgery. This has created interest in non-operative hemostatic strategies that might stabilize bleeding, avoid anesthesia exposure, reduce resource utilization, and shorten the pathway to definitive disposition.
Tranexamic acid is an antifibrinolytic agent that inhibits plasminogen activation and reduces fibrin clot breakdown. Systemic TXA has established use in trauma, postpartum hemorrhage, and selected surgical settings. Topical and nebulized approaches are especially attractive in upper airway bleeding because they may deliver local hemostatic benefit while limiting systemic exposure. In hemoptysis, for example, nebulized TXA has been increasingly used as a practical bedside intervention. Extending this concept to post-tonsillectomy bleeding is biologically plausible, but implementation in everyday hospital systems can lag behind initial enthusiasm.
The study by Lavin and colleagues is therefore notable not just for evaluating nebulized TXA in PTH, but for examining whether a structured implementation strategy can standardize its use and influence clinically meaningful outcomes.
Study Design and Quality Improvement Intervention
This was a quality improvement study using Model for Improvement methodology to create and implement a clinical care guideline for nebulized TXA in PTH. The intervention was not merely a recommendation; it included a practical algorithm and an order set designed to make treatment easy to identify and execute in the emergency department.
The authors compared data from two years before and two years after guideline initiation. This pre-implementation versus post-implementation framework is a common and useful approach for studying real-world practice change, especially when the goal is rapid adoption of a care process rather than explanatory efficacy testing under tightly controlled conditions.
Population and eligibility
The study evaluated patients who returned to the emergency department with post-tonsillectomy bleeding during the defined periods. The total number of tonsillectomies performed was 2805 in the pre-implementation period and 5382 in the post-implementation period. Emergency department returns for bleeding occurred in 70 patients before implementation and 155 patients after implementation.
The protocol defined eligibility for nebulized TXA as the presence of active bleeding or a visible blood clot in the tonsillar fossa. This is clinically sensible because the presence of a clot may indicate recent or ongoing bleeding risk even if active brisk hemorrhage is not observed during the encounter.
Intervention pathway
The clinical algorithm recommended three nebulized TXA treatments for eligible patients. Exclusion criteria were severe bleeding, absence of active bleeding or clot, and inability to tolerate nebulized treatment or protect the airway. These exclusions are important. They emphasize that nebulized TXA was intended for selected, hemodynamically and airway-stable patients and was not positioned as a substitute for immediate operative or resuscitative management when bleeding severity demanded escalation.
An order set supported implementation. In hospital medicine and emergency care, the presence of an order set often determines whether a protocol is consistently applied. It reduces cognitive load, improves prescribing accuracy, and helps orient rotating clinicians to local practice standards.
Outcomes assessed
The study examined several process and outcome measures: emergency department returns for PTH, TXA order set usage, frequency of TXA administration, returns to the operating room for hemorrhage control, and secondary returns to the emergency department. The primary clinically meaningful outcome was the rate of operative management for PTH.
Main Results
Emergency department presentations for hemorrhage
The rate of emergency department return for post-tonsillectomy bleeding was 2.5% before implementation and 2.9% after implementation. This difference was not statistically significant. Patient age did not differ between groups. These observations suggest that the populations were broadly similar with respect to at least one important baseline characteristic and that the intervention did not obviously change the threshold for return to care.
Implementation fidelity and protocol uptake
Among post-implementation patients, 126 of 155 patients with PTH, or 81.3%, met inclusion criteria for TXA treatment. This is a substantial proportion of all hemorrhage presentations, indicating that the algorithm covered a meaningful segment of routine clinical practice rather than only a narrow subgroup.
Order set utilization among patients receiving TXA in the emergency department was 95.7%. From an implementation science perspective, this is one of the most important findings in the paper. Many promising interventions fail not because they lack therapeutic potential, but because they are not reliably deployed. High order set use implies that the care pathway was successfully integrated into frontline workflow.
Operative management
The most consequential finding was the reduction in operative PTH management after CCG implementation. Before the intervention, 35 of 70 patients with emergency department PTH presentations, or 50.0%, required operative management. After implementation, 42 of 155 patients, or 27.1%, required operative management. This difference was statistically significant with p = 0.001.
The reported absolute risk reduction was 0.320, with a 95% confidence interval of 0.116 to 0.500. In practical terms, this means the post-implementation strategy was associated with roughly 32 fewer operative interventions per 100 PTH presentations, and the confidence interval suggests that even the lower-bound estimate still reflects a potentially meaningful benefit.
Expressed differently, the approximate number needed to treat based on the reported absolute risk reduction would be just over 3 patients to prevent one operative intervention, although this should be interpreted cautiously because the study was not randomized and the effect estimate may incorporate both the treatment and broader systems changes.
Secondary returns
The abstract notes that secondary emergency department returns were among the measures tracked, but the numerical result is not provided in the summary presented here. Without those data, it is difficult to determine whether reduced operating room utilization came at the cost of more recurrent presentations. That outcome would be important for judging whether the intervention primarily delayed surgery or genuinely stabilized bleeding in a durable way.
Safety
No safety signal is reported in the abstract. However, absence of reported adverse events is not equivalent to evidence of no harm. For nebulized TXA in upper airway bleeding, key practical concerns include bronchospasm, poor tolerance, ineffective delivery in severe hemorrhage, and delayed escalation in patients who need operative control. The study’s exclusion criteria partly mitigate these risks by avoiding use in patients with severe bleeding or inadequate airway protection.
Clinical Interpretation
This report is best interpreted as an implementation-focused effectiveness study. It does not simply ask whether TXA can work under ideal circumstances; it asks whether a hospital can operationalize TXA use in a way that meaningfully changes care pathways. The answer appears to be yes. The combination of a clear algorithm, explicit eligibility criteria, and an embedded order set achieved rapid and sustained uptake.
The reduction in operative management is clinically important. Operating room return after tonsillectomy carries burdens for patients, families, anesthesiology teams, surgeons, and hospitals. Avoiding an unnecessary return to the operating room may reduce anesthesia exposure, procedural risk, overnight admissions, and costs. It may be especially valuable in pediatric populations, where reoperation can be particularly stressful for both the patient and caregivers.
There is also a strong mechanistic rationale. Tonsillectomy beds are richly vascularized and subject to local fibrinolysis during healing. By inhibiting fibrin clot degradation, TXA may promote persistence of a forming or tenuous clot at the bleeding site. Nebulization offers a route to bathe the oropharyngeal mucosa and tonsillar fossae directly, though drug deposition in the exact area of hemorrhage likely varies depending on patient cooperation, anatomy, and ongoing bleeding.
Importantly, the study evaluates a package of care rather than TXA in isolation. The observed benefit may reflect several interacting factors: earlier treatment, more consistent triage, clearer escalation thresholds, better communication between emergency clinicians and otolaryngology, and protocolized identification of patients who can be safely observed versus those who require immediate surgery. That does not diminish the findings, but it does mean the effect cannot be attributed solely to the pharmacologic action of nebulized TXA.
Strengths and Limitations
Strengths
The study has several notable strengths. First, it addresses a real and common implementation gap in acute care. Second, the intervention is pragmatic and replicable: a bedside treatment algorithm plus an electronic order set is feasible in many hospitals. Third, the study includes a large denominator of tonsillectomies across two multi-year periods, helping contextualize the hemorrhage burden. Fourth, the outcome of operating room return is clinically meaningful and easily understood by stakeholders across specialties.
Limitations
The principal limitation is the pre-post, nonrandomized design. Temporal changes unrelated to the guideline may have influenced outcomes, including shifts in surgical technique, perioperative counseling, thresholds for admission, otolaryngology staffing patterns, or broader institutional practice. Regression to the mean and unmeasured confounding are possible.
The abstract does not provide granular details on bleeding severity, timing after surgery, proportion of primary versus secondary hemorrhage, hemodynamic status, or concomitant local interventions such as suctioning, topical vasoconstrictors, ice water gargles, bedside cautery, or direct pressure. These factors could materially affect the need for operative control.
The number of tonsillectomies nearly doubled in the post-implementation period, increasing from 2805 to 5382. While the emergency department return rate for bleeding remained similar, this change raises questions about whether referral patterns, case mix, or institutional volume evolved over time. It also remains unclear whether the same surgeons, patient populations, and perioperative protocols predominated across both periods.
Safety reporting is limited in the abstract. For broad practice change, clinicians will want more detailed data on adverse events, treatment tolerance, airway outcomes, and rates of delayed operative intervention after initial non-operative management.
Finally, generalizability may depend on local systems. Hospitals without rapid otolaryngology backup, standardized emergency order sets, or familiarity with nebulized hemostatic therapy may not reproduce the same results immediately.
Implications for Emergency and Otolaryngology Practice
Despite these limitations, the study offers a compelling model for structured PTH management. For emergency departments and ENT services considering adoption, several practical lessons emerge.
First, patient selection matters. Nebulized TXA should not distract from immediate airway assessment, hemodynamic stabilization, or urgent operative planning in severe hemorrhage. The study’s exclusion criteria are clinically appropriate and should likely remain central in local protocols.
Second, implementation infrastructure is crucial. A concise, visible algorithm and a readily accessible order set appear to be major determinants of success. Educational interventions alone are often insufficient in settings with rotating staff and variable experience.
Third, outcome tracking should extend beyond initial hemorrhage control. Programs adopting this strategy should monitor repeat bleeding, observation unit use, hospital admission, return to the operating room after discharge, adverse respiratory events, and patient-centered outcomes such as distress and length of stay.
Fourth, the findings may help standardize a frequently inconsistent area of care. PTH management often varies by clinician comfort, time of presentation, and local ENT availability. A shared protocol can improve consistency, reduce ambiguity, and potentially decrease unnecessary procedural escalation.
The study also raises important questions for future research. Randomized or prospective multicenter studies would help disentangle the effect of nebulized TXA from the effect of protocolization itself. Dose optimization, number of nebulized treatments, age-specific response, and comparative effectiveness against other non-operative measures also deserve investigation. Economic analyses would be especially useful, given the potential to reduce operating room utilization.
Funding, Registration, and Citation
Funding information was not provided in the source abstract available here.
A ClinicalTrials.gov registration number was not provided in the source abstract available here.
Citation: Lavin J, Billings K, Smith A, Patel K, Corboy J, Hazkani I. Clinical Care Guideline Implementation of Nebulized Tranexamic Acid in Post-Tonsillectomy Hemorrhage. Laryngoscope. 2026 May 29. doi: 10.1002/lary.70641. Epub ahead of print. PMID: 42212485.
Conclusion
Lavin and colleagues provide an instructive example of how a pragmatic clinical care guideline can translate an emerging therapy into routine emergency department practice. In patients with post-tonsillectomy hemorrhage who had active bleeding or a visible clot and who did not have severe bleeding or airway compromise, a protocol centered on three nebulized TXA treatments achieved very high uptake and was associated with a substantial reduction in returns to the operating room.
For clinicians, the key message is twofold. Nebulized TXA appears to be a promising non-operative adjunct for selected PTH presentations, and structured implementation may be as important as the drug itself. For institutions, the study supports developing explicit algorithms, embedding order sets, and maintaining strict escalation criteria for severe cases. For researchers, the next step is to confirm these benefits prospectively, define safety and durability more clearly, and determine which patients derive the greatest advantage.
Until then, this study meaningfully advances the conversation from whether nebulized TXA can be considered to how it can be reliably delivered in real-world acute care.